GRO J1744-28, search for the counterpart: infrared photometry and spectroscopy

Using VLT/ISAAC, we detected 2 candidate counterparts to the bursting pulsar GRO J1744-28, one bright and one faint, within the X-ray error circles of XMM-Newton and Chandra. In determining the spectral types of the counterparts we applied 3 different extinction corrections; one for an all-sky value, one for a Galactic Bulge value and one for a local value. We find the local value, with an extinction law of alpha = 3.23 +- 0.01 is the only correction that results in colours and magnitudes for both bright and faint counterparts consistent with a small range of spectral types, and for the bright counterpart, consistent with the spectroscopic identification. Photometry of the faint candidate indicates it is a K7/M0 V star at a distance of 3.75 +- 1 kpc. This star would require a very low inclination angle (i < 9deg) to satisfy the mass function constraints; however it cannot be excluded as the counterpart without follow-up spectroscopy to detect emission signatures of accretion. Photometry and spectroscopy of the bright candidate indicate it is most likely a G/K III star. The spectrum does not show Br-gamma emission, a known indicator of accretion. The bright star's magnitudes are in agreement with the constraints placed on a probable counterpart by the calculations of Rappaport & Joss (1997) for an evolved star that has had its envelope stripped. The mass function indicates the counterpart should have M < 0.3 Msol for an inclination of i >= 15deg; a stripped giant, or a main sequence M3+ V star are consistent with this mass-function constraint. In both cases mass-transfer, if present, will be by wind-accretion as the counterpart will not fill its Roche lobe given the observed orbital period. The derived magnetic field of 2.4 x 10^{11} G will inhibit accretion by the propeller effect, hence its quiescent state.Comment: 12 pages, 6 figures, 4 table, MNRAS accepted Changes to the content and an increased analysis of the Galactic centre extinctio

The low or retrograde spin of the first extragalactic microquasar: implications for Blandford-Znajek powering of jets

Transitions to high mass accretion rates in black hole X-ray binaries are associated with the ejection of powerful, relativistically moving jets. The mechanism that powers such events is thought to be linked to tapping of the angular momentum (spin) of the black hole, the rate of accretion through the disc or some combination of the two. We can attempt to discriminate between these different possibilities by comparing proxies for jet power with spin estimates. Because of the small number of sources that reach Eddington mass accretion rates and have therefore been suggested to act as ‘standard candles’, there has been much recent debate as to whether a significant correlation exists between jet power and black hole spin. We perform continuum fitting to the high-quality, disc-dominated XMM–Newton spectra of the extragalactic microquasar discovered in M31. Assuming prograde spin, we find that for sensible constraints the spin is always very low (a* ≤ 0.15 at 3s).When combined with a proxy for jet power derived from the maximum 5 GHz radio luminosity during a bright flaring event, we find that the source sits well above the previously reported, rising correlation that would indicate that spin tapping is the dominant mechanism for powering the jets, i.e. it is too ‘radio loud’ for such a low spin. The notable exceptions require the inclination to be improbably small or the jet to be very fast. We investigate whether this could be a byproduct of selecting prograde-only spin, finding that the data statistically favour a substantially retrograde spin for the same constraints (a* ≤-0.17 at 3s). Although theoretically improbable, this remarkable finding could be confirmation that retrograde spin can power such jets via spin-tapping, as has been suggested for certain radio quasars. In either case this work demonstrates the value of studying local extragalactic microquasars as a means to better understand the physics of jet launching

Archival VLBA observations of the Cygnus A Nuclear Radio Transient (Cyg A-2) Strengthen the Tidal Disruption Event Interpretation

We have analyzed archival VLBA data for Cygnus A between 2002 and 2013, to search for radio emission from the transient discovered in 2015 by \citet{per18} approximately 0.4\arcsec~ from the nucleus of Cygnus A (Cyg A-2). \citet{per18} use VLA and VLBA archival data (between 1989 and 1997) to show that the transient rises in flux density by a factor of at least five in less than approximately 20 years. With the additional data presented here, we revise the rise time to between approximately four years and six years, based on a new detection of the source at 15.4 GHz from October 2011. Our results strengthen the interpretation of Cyg A-2 as the result of a Tidal Disruption Event (TDE), as we can identify the location of the compact object responsible for the TDE and can estimate the angular expansion speed of the resulting radio emitting structures, equivalent to an apparent expansion speed of $<0.9c$. While our results are consistent with recent X-ray analyses, we can rule out a previously suggested date of early 2013 for the timing of the TDE. We favour a timing between early 2009 and late 2011. Applying the model of \citet{nak11}, we suggest a TDE causing a mildly relativistic outflow with a (density-dependent) total energy $>10^{49}$ erg. Due to the improved temporal coverage of our archival measurements, we find that it is unlikely that Cyg A-2 has previously been in a high luminosity radio state over the last 30 years.Comment: Eight pages, three figures, accepted to ApJ Letter

e-EVN radio detection of Aql X-1 in outburst

The neutron star X-ray binary Aql X-1 is currently in outburst. Using the European VLBI Network (e-EVN) we observed Aql X-1 at 5 GHz in two time-slots: 2013 June 18 between 19:48 - 20:36 UT (MJD 56461.825 - 56461.858), and 2013 June 19 between 02:53 - 05:54 UT (MJD 56462.120 - 56462.246). The two datasets were combined together and then calibrated

Treatment for inclusion body myositis

Background Inclusion body myositis (IBM) is a late-onset inflammatory muscle disease (myopathy) associated with progressive proximal and distal limb muscle atrophy and weakness. Treatment options have attempted to target inflammatory and atrophic features of this condition (for example with immunosuppressive and immunomodulating drugs, anabolic steroids, and antioxidant treatments), although as yet there is no known effective treatment for reversing or minimising the progression of inclusion body myositis. In this review we have considered the benefits, adverse effects, and costs of treatment in targeting cardinal effects of the condition, namely muscle atrophy, weakness, and functional impairment. Objectives To assess the effects of treatment for IBM. Search methods On 7 October 2014 we search ed the Cochrane Neuromuscular Disease Group Specialized Register, the Cochrane Central Register for Controlled Trials (CENTRAL), MEDLINE, and EMBASE. Additionally in November 2014 we searched clinical trials registries for ongoing or completed but unpublished trials. Selection criteria We considered randomised or quasi-randomised trials, including cross-over trials, of treatment for IBM in adults compared to placebo or any other treatment for inclusion in the review. We specifically excluded people with familial IBM and hereditary inclusion body myopathy, but we included people who had connective tissue and autoimmune diseases associated with IBM, which may or may not be identified in trials. We did not include studies of exercise therapy or dysphagia management, which are topics of other Cochrane systematic reviews. Data collection and analysis We used standard Cochrane methodological procedures. Main results The review included 10 trials (249 participants) using different treatment regimens. Seven of the 10 trials assessed single agents, and 3 assessed combined agents. Many of the studies did not present adequate data for the reporting of the primary outcome of the review, which was the percentage change in muscle strength score at six months. Pooled data from two trials of interferon beta-1a (n = 58) identified no important difference in normalised manual muscle strength sum scores from baseline to six months (mean difference (MD) -0.06, 95% CI -0.15 to 0.03) between IFN beta-1a and placebo (moderate-quality evidence). A single trial of methotrexate (MTX) (n = 44) provided moderate-quality evidence that MTX did not arrest or slow disease progression, based on reported percentage change in manual muscle strength sum scores at 12 months. None of the fully published trials were adequately powered to detect a treatment effect. We assessed six of the nine fully published trials as providing very low-quality evidence in relation to the primary outcome measure. Three trials (n = 78) compared intravenous immunoglobulin (combined in one trial with prednisone) to a placebo, but we were unable to perform meta-analysis because of variations in study analysis and presentation of trial data, with no access to the primary data for re-analysis. Other comparisons were also reported in single trials. An open trial of anti-T lymphocyte immunoglobulin (ATG) combined with MTX versus MTX provided very low-quality evidence in favour of the combined therapy, based on percentage change in quantitative muscle strength sum scores at 12 months (MD 12.50%, 95% CI 2.43 to 22.57). Data from trials of oxandrolone versus placebo, azathioprine (AZA) combined with MTX versus MTX, and arimoclomol versus placebo did not allow us to report either normalised or percentage change in muscle strength sum scores. A complete analysis of the effects of arimoclomol is pending data publication. Studies of simvastatin and bimagrumab (BYM338) are ongoing. All analysed trials reported adverse events. Only 1 of the 10 trials interpreted these for statistical significance. None of the trials included prespecified criteria for significant adverse events. Authors\u27 conclusions Trials of interferon beta-1a and MTX provided moderate-quality evidence of having no effect on the progression of IBM. Overall trial design limitations including risk of bias, low numbers of participants, and short duration make it difficult to say whether or not any of the drug treatments included in this review were effective. An open trial of ATG combined with MTX versus MTX provided very low-quality evidence in favour of the combined therapy based on the percentage change data given. We were unable to draw conclusions from trials of IVIg, oxandrolone, and AZA plus MTX versus MTX. We need more randomised controlled trials that are larger, of longer duration, and that use fully validated, standardised, and responsive outcome measures

Chandra high-resolution spectra of 4U 1630-47: the disappearance of the wind

We present the analysis of six Chandra X-ray high-resolution observations of the black hole low-mass X-ray binary 4U 1630-47 taken during its 2012–2013 outburst. Fe XXVI K α, K β, Fe XXV K α, K β, and Ca XX K α blueshifted absorption lines were identified in the first four observations, which correspond to soft accretion states. The remaining observations, associated to intermediate and possibly hard accretion states, do not show significant absorption features down to equivalent width of 1 eV for both Fe XXVI and Fe XXV. We inferred wind launching radii between 1.2 − 2.0 (1012 cm/n) × 1011 cm and column densities N(H) > 1023 cm−2. In the first four observations, we found that thermal pressure is likely to be the dominant launching mechanism for the wind, although such conclusions depend on the assumed density. We used the spectral energy distributions obtained from our continuum modelling to compute thermal stability curves for all observations using the XSTAR photoionization code. We found that the absence of lines in the transitional state cannot be attributed to an evolution of the plasma caused by thermal instabilities derived from the change in the continuum spectrum. In contrast, the disappearance of the wind could indicate an acceleration of the flow or that the plasma has been exhausted during the soft state